Prioritized Attributes to Better Define and Measure Innovation in Health Technology Assessment: Findings from an Expert Roundtable

Author(s)

Xie R1, Cheng YY2, Bright J3, Spangler J3, Krieger J4, Graglia M5, Chapman R3
1Innovation and Value Initiative, Newton, MA, USA, 2Innovation and Value Initiative, worcester, MA, USA, 3Innovation and Value Initiative, Alexandria, VA, USA, 4Harvard Business School, Newton, MA, USA, 5SynGAP Research Fund, Palo Alto, CA, USA

Presentation Documents

OBJECTIVES:

Accelerating innovations in different types of health technology call for improved methods and processes to better define and measure innovation in health technology assessment (HTA). Our objective was to engage cross-stakeholder experts to identify prioritized areas for future research to better define and measure the innovative properties of novel health technologies.

METHODS:

A targeted search was first conducted to identify systematic review articles for attributes used to define and measure innovation in HTA frameworks worldwide. Guidance documents from three HTA agencies not considered in the review articles were also examined. Based on the extractions, we compiled a starting list of attributes and categorized them into domains. An Expert Roundtable was subsequently held on October 17, 2020, where 11 stakeholders representing patient, employer, clinician, payer, industry, and researcher perspectives participated in facilitated group discussions to identify attributes that were missing and/or should be removed, and attributes that required additional research in methods and data. Participants voted on the top 3 attributes for future research. A discussion guide was developed to facilitate the roundtable.

RESULTS:

The initial list comprised 23 attributes across six domains including therapeutic properties, side effects and convenience, underlying health conditions, long-term dynamic effects, economic and social impacts, and equity impacts. Participants identified an additional 10 attributes that should be included (e.g., impacts on non-health sectors) and 4 attributes that should be removed (e.g., costs of the novel technology). A total of 14 attributes were identified as ones that needed additional research in methods and data, among which real-option value, scientific spillover, and broader societal impacts were voted as prioritized areas for research into measurement of innovation.

CONCLUSIONS:

Methods and data require transformation to better incorporate innovation considerations into HTA. Such improvements will help ensure long-term efficiency of our innovation system and ultimately improve social welfare.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

HTA75

Topic

Economic Evaluation, Health Technology Assessment, Patient-Centered Research, Study Approaches

Topic Subcategory

Novel & Social Elements of Value, Patient Engagement, Surveys & Expert Panels, Value Frameworks & Dossier Format

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×